Community-acquired pneumonia (CAP) infects upwards of four million people in the US each year, of which 20% require subsequent hospitalisation. Consequently, it is a large contributor to excessive healthcare resource consumption and cost. Since the aetiology of CAP is not identified in a...

Objective: To assess parental willingness to pay (WTP) for a shorter course of antibacterial treatment versus conventional antibacterial therapy for acute otitis media (AOM). Methods: The study population consisted of 562 parents of children who had been seen and treated by a paediatrician for...

Objective: To compare the cost effectiveness of sequential intravenous (IV) to oral ciprofloxacin plus metronidazole (CIP/MTZ IV/PO) with that of IV ciprofloxacin plus IV metronidazole (CIP/MTZ IV) and IV imipenem-cilastatin (IMI IV) in patients with intra-abdominal infections. Design and...

Background: Much has been published on the efficacy and cost effectiveness of Helicobacter pylori eradication treatment as an alternative to histamine H2-receptor antagonist maintenance treatment in peptic ulcer disease. However, most studies have analysed and emphasised H. pylori eradication...

Piperacillin/tazobactam is a beta-lactam/beta-lactamase inhibitor combination with a broad spectrum of antibacterial activity against most Gram-positive and Gram-negative aerobic bacteria and anaerobic bacteria. Piperacillin/tazobactam is effective and well-tolerated in patients with lower...

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity. Relatively few pharmacoeconomic studies have been conducted on this disease. This article reviews available information about the utilisation of healthcare resources and cost of care, and the cost or cost...

Background: Around 0.4 million cases of multidrug-resistant tuberculosis (MDR-TB) occur each year. Only a small fraction of these cases are treated according to international guidelines. Evidence relevant to decisions about whether to scale-up treatment for MDR-TB includes cost and...

Outpatient parenteral antibacterial therapy (OPAT) is an increasingly popular means of containing the costs of antibacterial therapy, by avoiding the need for hospitalisation or allowing early discharge from hospital, in patients with serious infections. It also offers increased comfort and...